Emerence Crompot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emerence Crompot has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Anne Farina
ICEP Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France
58 shared publications - Emilie Mamessier
Aix Marseille Univ, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, “ Predictive Oncology laboratory”, Label “Ligue contre le cancer”, Marseille, France
58 shared publications - Emmanuelle Charafe-Jauffret
CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France
58 shared publications - François Bertucci
Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
58 shared publications - Marc Lopez
Aix Marseille Univ, INSERM, CNRS, Institut Paoli-Calmettes, CRCM, (Predictive Oncology team, équipe labellisée Ligue nationale contre le cancer), Marseille, France
58 shared publications - Andreas Pahl
Heidelberg Pharma AG, Ladenburg, Germany
43 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 5 shows the analysis of average Drug Antibody Ratio in monkey plasma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 5 shows the analysis of average Drug Antibody Ratio in monkey plasma
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 2 shows IHC analysis of Nectin-4 expression on tumor tissue and human skin keratinocytes using 15A7.5
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 2 shows IHC analysis of Nectin-4 expression on tumor tissue and human skin keratinocytes using 15A7.5
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 3 shows the internalization of 15A7.5 and Ha22
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 3 shows the internalization of 15A7.5 and Ha22
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 2 shows the 6226 human plasma membrane and secreted proteins screened
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 2 shows the 6226 human plasma membrane and secreted proteins screened
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 1 shows apparent affinity of various chimeric mAbs and human HA22 anti-nectin-4 mAbs
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 1 shows apparent affinity of various chimeric mAbs and human HA22 anti-nectin-4 mAbs
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 3 shows the affinities (Octet) of anti-hnectin-4 mAbs for monomeric and dimeric human nectin-4
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 3 shows the affinities (Octet) of anti-hnectin-4 mAbs for monomeric and dimeric human nectin-4
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 4 shows the analysis of ETx-22 infiltration in SUM190PT tumors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 4 shows the analysis of ETx-22 infiltration in SUM190PT tumors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 5 shows IHC analysis of ETx-22 infiltration and pharmacodynamic in SUM190PT tumors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 5 shows IHC analysis of ETx-22 infiltration and pharmacodynamic in SUM190PT tumors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 1 shows epitope mapping of humanized 15A7.5 to human nectin-4
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Figure 1 shows epitope mapping of humanized 15A7.5 to human nectin-4
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 4 shows the PK data of ETx-22 in Cynomolgus monkeys
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Supplementary Table 4 shows the PK data of ETx-22 in Cynomolgus monkeys